Overview

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Collaborator:
National Cancer Institute (NCI)